Grant: Engage Plus Grants Program
University of British Columbia
$12,500.00
Testing of unique 3D-printed pancreatic tissues to confirm appropriate insulin-releasing function for the regulation of blood glucose in diabetes
FY 2018-19
Summary
Insulin replacement by implant of differentiated stem cells is a promising approach to treat diabetes, and is now*being tested clinically, including here in Vancouver. Initial findings from the clinical testing indicate that*improvements are required to improve graft vascularization, survival and function. Vancouver-based Aspect*Biosystems Ltd has developed cell bioprinting technology that may be able to address these limitations. Thus,*the goal of this project is to assess the survival and function of novel bioprinted 3D tissue containing human*embryonic stem cells (hESCs) differentiated toward insulin-producing cells. This work will expand on the first*phase of the project, previously funded by the NSERC Engage program, in which we collaborated with Aspect*to assess and optimize the viability of undifferentiated hESCs in bioprinted tissue. Based upon our progress, we*can now optimize the 3D pancreas tissue to determine which composition best supports cell viability and*function of differentiated hESCs. In vitro function of bioprinted cells will be assessed by measuring insulin*secretion in response to nutrients and beta cell secretagogues in a dynamic perifusion apparatus. Further testing*will be conducted in immunodeficient, diabetic rats to determine whether the bioprinted tissue is able to*reverse diabetes and restore control of glucose regulation. The Kieffer lab will provide Aspect with human ES*cells that have been differentiated toward insulin-producing cells. These cells will be bioprinted by Aspect into*living biocompatible 3D structures using Aspect's unique alginate/collagen bioink. The project will provide an*excellent training opportunity for students in cutting edge biomedical engineering at the interface of academia*and industry, and could lead to substantial investments in follow-up research and development.
Program
Engage Plus Grants Program
Recipient
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
536342-2018
Name nom
Kieffer, Timothy
Department département
Cellular and Physiological Sciences
Organization id
2
Institution établissement
University of British Columbia
Province en
British Columbia
Province fr
Colombie-Britannique
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2018
Competition year année de concours
2018
Award amount
12500
Program id
EGP2
Program name en
Engage Plus Grants Program
Program name fr
Programme de subvention d'engagement partenarial Plus
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1554
Committee name en
Pacific Internal Decision Committee
Committee name fr
Comité de décision interne pour le Pacifique
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
9000
Research subject group en
Medical sciences
Research subject group fr
Sciences médicales
Research subject en
Medical sciences
Research subject fr
Sciences médicales
Partie
1
Nb partie
1
Application title
Testing of unique 3D-printed pancreatic tissues to confirm appropriate insulin-releasing function for the regulation of blood glucose in diabetes
Keyword
NSERC
Application summary
Insulin replacement by implant of differentiated stem cells is a promising approach to treat diabetes, and is now*being tested clinically, including here in Vancouver. Initial findings from the clinical testing indicate that*improvements are required to improve graft vascularization, survival and function. Vancouver-based Aspect*Biosystems Ltd has developed cell bioprinting technology that may be able to address these limitations. Thus,*the goal of this project is to assess the survival and function of novel bioprinted 3D tissue containing human*embryonic stem cells (hESCs) differentiated toward insulin-producing cells. This work will expand on the first*phase of the project, previously funded by the NSERC Engage program, in which we collaborated with Aspect*to assess and optimize the viability of undifferentiated hESCs in bioprinted tissue. Based upon our progress, we*can now optimize the 3D pancreas tissue to determine which composition best supports cell viability and*function of differentiated hESCs. In vitro function of bioprinted cells will be assessed by measuring insulin*secretion in response to nutrients and beta cell secretagogues in a dynamic perifusion apparatus. Further testing*will be conducted in immunodeficient, diabetic rats to determine whether the bioprinted tissue is able to*reverse diabetes and restore control of glucose regulation. The Kieffer lab will provide Aspect with human ES*cells that have been differentiated toward insulin-producing cells. These cells will be bioprinted by Aspect into*living biocompatible 3D structures using Aspect's unique alginate/collagen bioink. The project will provide an*excellent training opportunity for students in cutting edge biomedical engineering at the interface of academia*and industry, and could lead to substantial investments in follow-up research and development.